RICHMOND, Va. — New research from VCU Massey Cancer Center — published this week in Cell Reports — demonstrated that a novel targeted therapy could be an effective treatment option
Novel targeted therapy could be effective treatment option for deadly childhood cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: This image shows expression of a specific ferroptosis marker called TfR1 in MYCN-amplified neuroblastoma tissues before and after treatment with auranofin, an FDA-approved drug for rheumatoid arthritis. view more
Credit: VCU Massey Cancer Center
Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths.
Anthony Faber, Ph.D., and a team of researchers at VCU Massey Cancer Center were awarded a grant from the American Cancer Society to study how MYCN and an abundance of iron can drive cancer cell death in neuroblastoma and potentially be targeted with novel treatments. This award is the first part of a potential two-stage grant worth a combined total of $600,000.